Moreover, at present, the great majority of FDA approved therapeutic antibodies against tumour associated antigens (e.g. anti-CD20, anti-CD30, anti-EGFR, anti-HER-2 mAbs) are the humanised/chimeric IgG1 version of the mouse mAbs due to their superior ADCC (antibody-dependent cell-mediated cytotoxicity) and/or CDC (complement-dependent cytotoxicity) functions, or conjugated to toxins and radioactive substances to deliver lethal doses of such agents to the tumour. Here, ERBB2 is linked to neoplasm.